<p>Kornitzer Capital Management Inc. KS 在最近向证券交易委员会提交的文件中表示，在第四季度购买了 Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 免费报告) 的新股份。该基金购买了 22,091 股公司股票，价值约 911,000 美元。</p>
<p>其他几家大型投资者也增加或减少了在 KNSA 的持股。Amundi 在第一季度购买了价值 348,000 美元的 Kiniksa Pharmaceuticals International 新股份。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 4.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 现在拥有 22,843 股公司股票，价值 507,000 美元，此前在此期间又购买了 1,002 股。Millennium Management LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 8.7%。Millennium Management LLC 现在拥有 847,124 股公司股票，价值 18,815,000 美元，此前在此期间又购买了 67,452 股。Creative Planning 在第二季度购买了价值约 358,000 美元的 Kiniksa Pharmaceuticals International 新股份。最后，Quantbot Technologies LP 在第二季度购买了价值约 43,000 美元的 Kiniksa Pharmaceuticals International 新股份。机构投资者持有公司 53.95% 的股份。</p>
<h2>内部人士下注</h2>
<p>在 Kiniksa Pharmaceuticals International 的其他新闻中，首席会计官 Michael R. Megna 于 4 月 9 日星期四出售了 6,625 股公司股票。该股票以平均价格 46.69 美元出售，总价值为 309,321.25 美元。交易完成后，首席会计官持有 27,418 股公司股票，价值约 1,280,146.42 美元。此次交易使其持股减少了 19.46%。该出售在向证券交易委员会的文件中披露，可以通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席执行官 Sanj K. Patel 于 4 月 28 日星期二出售了 483,654 股公司股票。该股票以平均价格 51.86 美元出售，总价值为 25,082,296.44 美元。交易完成后，首席执行官直接持有 431,904 股公司股票，价值约 22,398,541.44 美元。此次交易使其持股减少了 52.83%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去 90 天内，内部人士共出售了价值 32,490,737 美元的 630,652 股公司股票。公司内部人士持有公司 53.48% 的股份。</p>
<h2>更多 Kiniksa Pharmaceuticals International 新闻</h2>
<p>以下是本周影响 Kiniksa Pharmaceuticals International 的主要新闻：</p>
<ul>
<li>积极情绪：第一季度超出预期并上调指引——Kiniksa 报告每股收益 0.27 美元，超过 0.18 美元的市场共识，收入为 2.143 亿美元（≈同比增长 55%）；管理层上调了 2026 财年的收入指引，提高了近期收入的可见性。第一季度业绩及指引</li>
<li>积极情绪：分析师上调评级/目标价——多家券商上调了目标价（例如：Jefferies 至 71 美元，Canaccord 至 64 美元，Citi 至 60 美元，Wedbush 至 59 美元），这支持了买入兴趣并推动股价上涨。分析师目标价上调</li>
<li>积极情绪：产品和管道势头——ARCALYST 报告第一季度净产品收入强劲，管理层上调了预期；KPL-387 第二阶段结果（复发性心包炎）预计在 2026 年下半年发布，计划在年底前启动第三阶段，提供未来催化剂。产品及管道</li>
<li>中性情绪：财报材料可用——第一季度幻灯片和电话会议记录已发布，供希望验证渠道动态、利润假设和指引驱动因素的投资者使用。财报演示</li>
<li>消极情绪：内部人士大量出售——首席执行官 Sanj K. Patel 在预先安排的 10b5-1 计划下进行了大量出售（包括 4 月 28 日出售的 483,654 股以及 4 月 29-30 日的其他批次）；董事 Barry Quart 也出售了约 13,000 股。大量内部人士出售可能会在短期内产生消极情绪，尽管是预先计划的。首席执行官 SEC 文件</li>
<li>消极情绪：董事出售细节——董事 Barry D. Quart 在 10b5-1 计划下出售了 13,099 股（平均约 50.10 美元），大幅减少了其持股；更多 SEC 文件在此。董事 SEC 文件</li>
</ul>
<h2>Kiniksa Pharmaceuticals International 股价表现</h2>
<p>KNSA 股票在周一开盘价为 55.27 美元。Kiniksa Pharmaceuticals International, plc 的 1 年最低价为 24.85 美元，1 年最高价为 55.28 美元。该公司的 50 日移动平均价格为 46.40 美元，200 日移动平均价格为 43.20 美元。该股票的市值为 42.3 亿美元，市盈率为 61.41，贝塔值为 0.17。</p>
<p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 获取免费报告) 最近于 4 月 28 日星期二发布了其财报。该公司报告第一季度每股收益为 0.27 美元，超出分析师共识预期的 0.18 美元 0.09 美元。Kiniksa Pharmaceuticals International 的股本回报率为 13.26%，净利润率为 9.69%。该公司在该季度的收入为 2.1427 亿美元，而分析师预期为 2.0611 亿美元。在去年同期，该公司每股收益为 0.11 美元。Kiniksa Pharmaceuticals International 的收入同比增长 55.5%。分析师预计 Kiniksa Pharmaceuticals International, plc 在当前年度将发布每股收益 1.22 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>最近，一些分析师对该股票发表了看法。华尔街禅在周一的研究报告中将 Kiniksa Pharmaceuticals International 的股票评级从 “持有” 上调至 “强力买入”。杰富瑞金融集团在 4 月 28 日的研究报告中将 Kiniksa Pharmaceuticals International 的股票目标价从 58.00 美元上调至 71.00 美元，并给予该股票 “买入” 评级。富国银行在 4 月 29 日的研究报告中将 Kiniksa Pharmaceuticals International 的股票目标价从 53.00 美元上调至 57.00 美元，并给予该股票 “增持” 评级。韦斯评级在 4 月 21 日的研究报告中重申了 Kiniksa Pharmaceuticals International 的 “持有（c）” 评级。最后，加拿大皇家银行在 4 月 29 日的研究报告中将 Kiniksa Pharmaceuticals International 的股票目标价从 62.00 美元上调至 64.00 美元，并给予该股票 “买入” 评级。七位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Kiniksa Pharmaceuticals International 目前的平均评级为 “适度买入”，平均目标价为 60.86 美元。</p>
<p><strong>获取我们最新的 KNSA 股票分析</strong></p>
<h2>Kiniksa Pharmaceuticals International 公司简介</h2>
<p>（免费报告）</p>
<p>Kiniksa Pharmaceuticals International, Inc 是一家生物制药公司，专注于发现、收购和开发治疗因免疫介导的疾病而遭受生命威胁和致残的患者的疗法。公司成立于 2013 年，总部位于马萨诸塞州列克星敦，Kiniksa 采用以患者为中心的方法，建立多样化的已上市药物和临床阶段候选药物组合，针对炎症和免疫学。公司的核心使命是通过推进新型和差异化的疗法，解决具有重大未满足医疗需求的复杂病症。</p>
<p>该公司的主要上市产品是 Ilaris（canakinumab），一种用于治疗与冷刺激相关的周期性综合症、系统性青少年特发性关节炎、成人发病的 Still 病和施尼茨勒综合症的白介素-1β抑制剂。</p>
<h2>另请参见</h2>
<ul>
<li>五只我们认为比 Kiniksa Pharmaceuticals International 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Kiniksa Pharmaceuticals International 吗？</h2>
<p>在考虑 Kiniksa Pharmaceuticals International 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Kiniksa Pharmaceuticals International 并不在名单上。</p>
<p>虽然 Kiniksa Pharmaceuticals International 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KNSA

<p>Kornitzer Capital Management Inc. KS 在第四季度收购了 Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) 的新股份，购买了 22,091 股，价值约 911,000 美元。其他机构投资者也调整了他们的持股。最近的内部销售包括首席执行官 Sanj K. Patel 出售了 483,654 股，这引发了对内部人士出售的担忧，尽管第一季度的业绩良好且分析师进行了升级。KNSA 股票开盘价为 55.27 美元，市值为 42.3 亿美元，市盈率为 61.41</p>

<p>Kornitzer Capital Management Inc. KS purchased a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund purchased 22,091 shares of the company's stock, valued at approximately $911,000.</p>
<div class="lb-trans"><p>Kornitzer Capital Management Inc. KS 在最近向证券交易委员会提交的文件中表示，在第四季度购买了 Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 免费报告) 的新股份。该基金购买了 22,091 股公司股票，价值约 911,000 美元。</p>
</div><p>Several other large investors have also added to or reduced their stakes in KNSA. Amundi bought a new stake in Kiniksa Pharmaceuticals International in the first quarter valued at $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Kiniksa Pharmaceuticals International by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company's stock worth $507,000 after buying an additional 1,002 shares during the period. Millennium Management LLC grew its position in shares of Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company's stock worth $18,815,000 after buying an additional 67,452 shares during the period. Creative Planning purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth about $358,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth about $43,000. Institutional investors own 53.95% of the company's stock.</p>
<div class="lb-trans"><p>其他几家大型投资者也增加或减少了在 KNSA 的持股。Amundi 在第一季度购买了价值 348,000 美元的 Kiniksa Pharmaceuticals International 新股份。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 4.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 现在拥有 22,843 股公司股票，价值 507,000 美元，此前在此期间又购买了 1,002 股。Millennium Management LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 8.7%。Millennium Management LLC 现在拥有 847,124 股公司股票，价值 18,815,000 美元，此前在此期间又购买了 67,452 股。Creative Planning 在第二季度购买了价值约 358,000 美元的 Kiniksa Pharmaceuticals International 新股份。最后，Quantbot Technologies LP 在第二季度购买了价值约 43,000 美元的 Kiniksa Pharmaceuticals International 新股份。机构投资者持有公司 53.95% 的股份。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 6,625 shares of the business's stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $46.69, for a total value of $309,321.25. Following the completion of the transaction, the chief accounting officer owned 27,418 shares of the company's stock, valued at approximately $1,280,146.42. The trade was a 19.46% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of the business's stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $51.86, for a total value of $25,082,296.44. Following the completion of the transaction, the chief executive officer directly owned 431,904 shares of the company's stock, valued at approximately $22,398,541.44. This trade represents a 52.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 630,652 shares of company stock worth $32,490,737 in the last 90 days. Corporate insiders own 53.48% of the company's stock.</p>
<div class="lb-trans"><p>在 Kiniksa Pharmaceuticals International 的其他新闻中，首席会计官 Michael R. Megna 于 4 月 9 日星期四出售了 6,625 股公司股票。该股票以平均价格 46.69 美元出售，总价值为 309,321.25 美元。交易完成后，首席会计官持有 27,418 股公司股票，价值约 1,280,146.42 美元。此次交易使其持股减少了 19.46%。该出售在向证券交易委员会的文件中披露，可以通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席执行官 Sanj K. Patel 于 4 月 28 日星期二出售了 483,654 股公司股票。该股票以平均价格 51.86 美元出售，总价值为 25,082,296.44 美元。交易完成后，首席执行官直接持有 431,904 股公司股票，价值约 22,398,541.44 美元。此次交易使其持股减少了 52.83%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去 90 天内，内部人士共出售了价值 32,490,737 美元的 630,652 股公司股票。公司内部人士持有公司 53.48% 的股份。</p>
</div><h2>More Kiniksa Pharmaceuticals International News</h2>
<div class="lb-trans"><h2>更多 Kiniksa Pharmaceuticals International 新闻</h2>
</div><p>Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:</p>
<div class="lb-trans"><p>以下是本周影响 Kiniksa Pharmaceuticals International 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Q1 beat and upgraded guidance — Kiniksa reported $0.27 EPS vs. $0.18 consensus and revenue of $214.3M (≈+55% YoY); management raised FY‑2026 revenue guidance, improving near‑term revenue visibility. Q1 Results &amp; Guidance</li>
<li>Positive Sentiment: Analyst upgrades/target raises — multiple brokers lifted targets (examples: Jefferies to $71, Canaccord to $64, Citi to $60, Wedbush to $59), which supports buying interest and helped push the stock higher. Analyst Target Raises</li>
<li>Positive Sentiment: Product and pipeline momentum — ARCALYST reported strong Q1 net product revenue and management raised expectations; KPL‑387 Phase‑2 readout (recurrent pericarditis) is expected 2H‑2026 with a planned Phase‑3 start by year‑end, offering future catalysts. Product &amp; Pipeline</li>
<li>Neutral Sentiment: Earnings materials available — Q1 slide deck and call transcript posted for investors who want to verify channel dynamics, margin assumptions and guidance drivers. Earnings Presentation</li>
<li>Negative Sentiment: Large insider selling — CEO Sanj K. Patel executed significant sales (including 483,654 shares on Apr. 28 and additional tranches Apr. 29–30) under a pre‑arranged 10b5‑1 plan; director Barry Quart also sold ~13k shares. Heavy insider selling can create short‑term negative sentiment despite being pre‑planned. CEO SEC Filing</li>
<li>Negative Sentiment: Director sale detail — Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a 10b5‑1 plan, reducing his stake materially; additional SEC filing here. Director SEC Filing</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第一季度超出预期并上调指引——Kiniksa 报告每股收益 0.27 美元，超过 0.18 美元的市场共识，收入为 2.143 亿美元（≈同比增长 55%）；管理层上调了 2026 财年的收入指引，提高了近期收入的可见性。第一季度业绩及指引</li>
<li>积极情绪：分析师上调评级/目标价——多家券商上调了目标价（例如：Jefferies 至 71 美元，Canaccord 至 64 美元，Citi 至 60 美元，Wedbush 至 59 美元），这支持了买入兴趣并推动股价上涨。分析师目标价上调</li>
<li>积极情绪：产品和管道势头——ARCALYST 报告第一季度净产品收入强劲，管理层上调了预期；KPL-387 第二阶段结果（复发性心包炎）预计在 2026 年下半年发布，计划在年底前启动第三阶段，提供未来催化剂。产品及管道</li>
<li>中性情绪：财报材料可用——第一季度幻灯片和电话会议记录已发布，供希望验证渠道动态、利润假设和指引驱动因素的投资者使用。财报演示</li>
<li>消极情绪：内部人士大量出售——首席执行官 Sanj K. Patel 在预先安排的 10b5-1 计划下进行了大量出售（包括 4 月 28 日出售的 483,654 股以及 4 月 29-30 日的其他批次）；董事 Barry Quart 也出售了约 13,000 股。大量内部人士出售可能会在短期内产生消极情绪，尽管是预先计划的。首席执行官 SEC 文件</li>
<li>消极情绪：董事出售细节——董事 Barry D. Quart 在 10b5-1 计划下出售了 13,099 股（平均约 50.10 美元），大幅减少了其持股；更多 SEC 文件在此。董事 SEC 文件</li>
</ul>
</div><h2>Kiniksa Pharmaceuticals International Price Performance</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 股价表现</h2>
</div><p>KNSA stock opened at $55.27 on Monday. Kiniksa Pharmaceuticals International, plc has a 1-year low of $24.85 and a 1-year high of $55.28. The business has a fifty day moving average price of $46.40 and a 200-day moving average price of $43.20. The stock has a market capitalization of $4.23 billion, a P/E ratio of 61.41 and a beta of 0.17.</p>
<div class="lb-trans"><p>KNSA 股票在周一开盘价为 55.27 美元。Kiniksa Pharmaceuticals International, plc 的 1 年最低价为 24.85 美元，1 年最高价为 55.28 美元。该公司的 50 日移动平均价格为 46.40 美元，200 日移动平均价格为 43.20 美元。该股票的市值为 42.3 亿美元，市盈率为 61.41，贝塔值为 0.17。</p>
</div><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The business had revenue of $214.27 million during the quarter, compared to analyst estimates of $206.11 million. During the same quarter in the previous year, the firm earned $0.11 EPS. Kiniksa Pharmaceuticals International's revenue was up 55.5% on a year-over-year basis. As a group, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.22 earnings per share for the current year.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 获取免费报告) 最近于 4 月 28 日星期二发布了其财报。该公司报告第一季度每股收益为 0.27 美元，超出分析师共识预期的 0.18 美元 0.09 美元。Kiniksa Pharmaceuticals International 的股本回报率为 13.26%，净利润率为 9.69%。该公司在该季度的收入为 2.1427 亿美元，而分析师预期为 2.0611 亿美元。在去年同期，该公司每股收益为 0.11 美元。Kiniksa Pharmaceuticals International 的收入同比增长 55.5%。分析师预计 Kiniksa Pharmaceuticals International, plc 在当前年度将发布每股收益 1.22 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of analysts have recently weighed in on the stock. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Monday. Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, April 28th. Wells Fargo &amp; Company upped their price target on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, April 29th. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, April 21st. Finally, Canaccord Genuity Group upped their price target on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, April 29th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $60.86.</p>
<div class="lb-trans"><p>最近，一些分析师对该股票发表了看法。华尔街禅在周一的研究报告中将 Kiniksa Pharmaceuticals International 的股票评级从 “持有” 上调至 “强力买入”。杰富瑞金融集团在 4 月 28 日的研究报告中将 Kiniksa Pharmaceuticals International 的股票目标价从 58.00 美元上调至 71.00 美元，并给予该股票 “买入” 评级。富国银行在 4 月 29 日的研究报告中将 Kiniksa Pharmaceuticals International 的股票目标价从 53.00 美元上调至 57.00 美元，并给予该股票 “增持” 评级。韦斯评级在 4 月 21 日的研究报告中重申了 Kiniksa Pharmaceuticals International 的 “持有（c）” 评级。最后，加拿大皇家银行在 4 月 29 日的研究报告中将 Kiniksa Pharmaceuticals International 的股票目标价从 62.00 美元上调至 64.00 美元，并给予该股票 “买入” 评级。七位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Kiniksa Pharmaceuticals International 目前的平均评级为 “适度买入”，平均目标价为 60.86 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on KNSA</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 KNSA 股票分析</strong></p>
</div><h2>Kiniksa Pharmaceuticals International Profile</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International, Inc 是一家生物制药公司，专注于发现、收购和开发治疗因免疫介导的疾病而遭受生命威胁和致残的患者的疗法。公司成立于 2013 年，总部位于马萨诸塞州列克星敦，Kiniksa 采用以患者为中心的方法，建立多样化的已上市药物和临床阶段候选药物组合，针对炎症和免疫学。公司的核心使命是通过推进新型和差异化的疗法，解决具有重大未满足医疗需求的复杂病症。</p>
</div><p>The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.</p>
<div class="lb-trans"><p>该公司的主要上市产品是 Ilaris（canakinumab），一种用于治疗与冷刺激相关的周期性综合症、系统性青少年特发性关节炎、成人发病的 Still 病和施尼茨勒综合症的白介素-1β抑制剂。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参见</h2>
</div><ul>
<li>Five stocks we like better than Kiniksa Pharmaceuticals International</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Kiniksa Pharmaceuticals International 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=KNSA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Kiniksa Pharmaceuticals International 吗？</h2>
</div><p>Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Kiniksa Pharmaceuticals International 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Kiniksa Pharmaceuticals International 并不在名单上。</p>
</div><p>While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kiniksa Pharmaceuticals International 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kornitzer Capital Management Inc. KS 购买了 Kiniksa Pharmaceuticals International, plc 的新股 $KNSA